Can CONMED's (CNMD) Guidance Miss Reshape Its Competitive Edge in Medical Technology?

• In its latest financial update, CONMED exceeded analysts' revenue expectations but reported the slowest revenue growth and weakest full-year guidance among peer medical technology companies.
• This relative underperformance stood out even more as competitors Zimmer Biomet and STERIS both delivered stronger operational results and outlooks during the same period.
• To assess the impact of CONMED's weak full-year guidance, we'll explore what this means for its previously outlined investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

CONMED Investment Narrative Recap

For investors considering CONMED, the core argument remains tied to the belief that the ongoing shift toward minimally invasive surgery, robust recurring revenue from key products, and regulatory tailwinds will eventually translate into sustained long-term growth. However, with the most recent earnings update revealing the slowest revenue growth and weakest full-year outlook among peers, the short-term catalyst of a margin rebound now seems less at risk than before, while the biggest risk, persistent market share loss, has become even more immediate as competitors deliver stronger results. The recent financial update signals that while the value proposition endures, the pathway to share recovery in orthopedics faces higher hurdles given these peer comparisons.

Among recent announcements, the revised full-year 2025 guidance stands out as most relevant. Management’s updated expectations for revenue and near-term performance underscore caution, especially as supply chain improvements and operating momentum in orthopedics are central to CONMED’s growth story. The narrowed outlook draws investor attention squarely to the company’s ability to execute on promised operational improvements, key to delivering the margin expansion and share gains that anchor the long-term narrative.

In contrast, investors should be aware that if market share recovery in orthopedics slips further...

Read the full narrative on CONMED (it's free!)

CONMED's narrative projects $1.6 billion revenue and $154.0 million earnings by 2028. This requires 5.7% yearly revenue growth and a $43.8 million earnings increase from $110.2 million today.

Uncover how CONMED's forecasts yield a $61.00 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided two fair value estimates for CONMED ranging from US$55 to US$61 per share. While some see upside potential, persistent competition for market share could shape the company’s future direction and define its next phase of performance, explore how others interpret these signals and what they mean for you.

Explore 2 other fair value estimates on CONMED - why the stock might be worth as much as 26% more than the current price!

Build Your Own CONMED Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CONMED research is our analysis highlighting 6 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CONMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CONMED's overall financial health at a glance.

No Opportunity In CONMED?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 37 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com